IL17A and neoplasm: For IL-17A, its peak levels in submucosal invasion and notable decrease in cases with organ metastases suggest its contribution to tumor invasiveness by promoting the epithelial–mesenchymal transition (EMT) in earlier stages [46], with a potential diminished immune activation in advanced metastatic disease.